Analysis of inhibiting the invasion and metastasis in oral squamous cell carcinoma

抑制口腔鳞癌侵袭转移的作用分析

• 批准号: 22592250
• 负责人: YOKOE Hidetaka
• 金额: $ 2.75万
• 依托单位: National Defense Medical College
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22592250/
• 关键词: 細胞接着因子; 癌転移抑制法; 癌浸潤抑制法; KCNJ2; β-catenin; βcatenin; KCNJ; Lin7C

The aim of this study was to develop a new method of inhibiting the invasion and metastasis of oral squamous cell carcinoma (OSCC) through the activating KCNJ2-Lin7C-CASK-βcatenin pathway. As the result of suppressed expression of KCNJ2 which located upstream of βcatenin, βcatenin expression levels were increased. In addition, we identified some molecules of upstream of KCNJ2 by the Ingenuity Pathway Analysis, and then focused amiodarone which is the drug of ventricular tachycardia. After treatment with this drug, expression levels of Lin7C, CASK and βcatenin were significantly up-regulated. We suggested that the specific KCNJ2 inhibitor, amiodarone, closely related to KCNJ2-Lin7C-CASK-βcatenin pathway, and therefore might be a therapeutic agent for cancer invasion and metastasis.

这项研究的目的是开发一种新方法，以抑制通过激活的KCNJ2-LIN7C-cask-βCatenin途径抑制口腔鳞状细胞癌（OSCC）的侵袭和转移。由于位于βCatenin上游的KCNJ2表达的结果，βCatenin表达水平增加了。此外，我们通过Ingenuity途径分析确定了KCNJ2上游的某些分子，然后聚焦于心脏心动过速的药物。用这种药物治疗后，LIN7C，桶和βcatenin的表达水平显着上调。我们建议特定的KCNJ2抑制剂Amidarone与KCNJ2-LIN7C-cask-βCatenin途径密切相关，因此可能是癌症侵袭和转移的治疗剂。